---
title: "Selected Expert Topics in Molecular Pathology and Precision Oncology"
canonical_url: "https://www.newpathology.de/expert-topics"
language: "en"
site: "New Pathology"
---
# Selected Expert Topics in Molecular Pathology and Precision Oncology

This page lists selected topics that are frequently addressed in consulting projects, expert interviews, and discovery discussions. The emphasis is on molecular pathology, precision oncology, biomarkers, digital pathology and AI-enabled workflows, reimbursement, and market access for oncology diagnostics in Germany and Europe.

## Selected keywords and consulting topics

- molecular pathology consulting
- oncology biomarker strategy
- liquid biopsy diagnostics
- minimal residual disease (MRD (measurable/minimal residual disease)) testing
- ctDNA (circulating tumor DNA) monitoring
- tumor mutational burden (TMB (tumor mutational burden))
- homologous recombination deficiency (HRD (homologous recombination deficiency))
- microsatellite instability (MSI)
- complex biomarker analysis
- ESR1 mutations
- PD-L1 testing
- HER2 diagnostics
- NGS (next-generation sequencing) panel design
- hybrid capture NGS (next-generation sequencing)
- reimbursement molecular diagnostics Germany
- EBM (Einheitlicher Bewertungsmaßstab) molecular diagnostics
- GOÄ molecular pathology
- DRG implementation molecular diagnostics
- precision oncology programs
- companion diagnostics strategy
- digital pathology strategy
- AI in pathology
- large language models in pathology
- pathology workflow software
- LIMS (laboratory information management system) integration pathology
- structured reporting pathology

## Expert Interviews

Expert interviews and consulting discussions can be provided on topics including molecular pathology, oncology biomarkers, next-generation sequencing, liquid biopsy, and minimal residual disease (MRD (measurable/minimal residual disease)) detection in solid tumors.

Expert interviews are frequently conducted for:

- pharmaceutical companies
- biotechnology companies
- diagnostics developers
- healthcare investors
- market research firms
- expert networks

Expert interviews can be conducted in English, German, and Dutch.

## Molecular Pathology & Precision Oncology

- Molecular pathology consulting for oncology programs
- Precision oncology consulting and tumor board workflows
- Design of integrated pathology workflows for genomic profiling
- Interpretation of complex genomic reports in solid tumors
- Integration of molecular results into clinical decision pathways

## NGS, WGS, WES & Panels

- Next-generation sequencing oncology assay selection
- Hybrid capture NGS (next-generation sequencing) and NGS (next-generation sequencing) panel design for solid tumors and hematology
- Whole genome sequencing (WGS (whole genome sequencing)) and whole exome sequencing (WES (whole exome sequencing)) in translational projects
- Comparing targeted NGS (next-generation sequencing) vs. WGS (whole genome sequencing)/WES (whole exome sequencing) for clinical questions
- Quality, coverage, and reporting standards for genomic diagnostics

## Liquid Biopsy & MRD

- Liquid biopsy diagnostics and ctDNA (circulating tumor DNA) testing strategies
- Analytical and clinical aspects of ctDNA (circulating tumor DNA) assays
- Minimal residual disease (MRD (measurable/minimal residual disease)) analysis in solid tumors and tumor-informed MRD (measurable/minimal residual disease) assays
- Use of MRD (measurable/minimal residual disease) readouts in clinical trials and routine care
- Positioning of liquid biopsy in existing pathology workflows

## Biomarkers & IHC

- Complex biomarker analysis, including TMB (tumor mutational burden), HRD (homologous recombination deficiency), and MSI implementation in oncology
- ESR1 mutation testing and monitoring in breast cancer
- PD-L1 testing and reporting standards
- HER2 diagnostics, including HER2-low and discordant cases
- MTAP biomarker strategies and co-deletion patterns
- Immunohistochemistry biomarkers and multiplex IHC (immunohistochemistry) concepts

## Genomic Profiling & Workflows

- Genomic profiling strategies for early- and late-line oncology
- Turnaround time and sample logistics in molecular pathology
- Pathology workflows for reflex testing and triage
- Data interpretation and variant classification processes
- Reporting formats and communication with clinical teams

## Reimbursement & Market Access

- Reimbursement pathways for molecular diagnostics in Germany
- EBM (Einheitlicher Bewertungsmaßstab) reimbursement molecular diagnostics and coding options
- GOÄ molecular pathology billing in private care
- IV (integrierte Versorgung) contracts Germany and selective contracting models
- Oncology diagnostics reimbursement Europe across key markets
- Market access molecular diagnostics and adoption barriers

## Digital Pathology, Software & AI

- Digital pathology strategy and implementation in diagnostic laboratories
- Software-supported pathology workflows, laboratory automation, and structured reporting
- Integration with LIMS (laboratory information management system) and clinical systems
- AI and large-language-model applications in pathology (transcription, report generation, retrieval)
- Prototyping and development of software solutions for pathology and molecular diagnostics
- IT architectures, local and cloud-based AI infrastructure, and interoperability
- Practical deployment requirements for AI-enabled workflows in pathology laboratories